{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:32:25Z","timestamp":1795059145462,"version":"4.10.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA210085"],"award-info":[{"award-number":["CA210085"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Current KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    (OFF) inhibitors that target inactive GDP-bound KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    cause responses in less than half of patients and these responses are not durable. A class of RAS\n                    <jats:sup>G12C<\/jats:sup>\n                    (ON) inhibitors that targets active GTP-bound KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    blocks ERK signaling more potently than the inactive-state inhibitors. Sensitivity to either class of agents is strongly correlated with inhibition of mTORC1 activity. We have previously shown that PI3K\/mTOR and ERK-signaling pathways converge on key cellular processes and that inhibition of both pathways is required for inhibition of these processes and for significant antitumor activity. We find here that the combination of a KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    inhibitor with a selective mTORC1 kinase inhibitor causes synergistic inhibition of Cyclin D1 expression and cap-dependent translation. Moreover, BIM upregulation by KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    inhibition and inhibition of MCL-1 expression by the mTORC1 inhibitor are both required to induce significant cell death. In vivo, this combination causes deep, durable tumor regressions and is well tolerated. This study suggests that the ERK and PI3K\/mTOR pathways each mitigate the effects of inhibition of the other and that combinatorial inhibition is a potential strategy for treating KRAS\n                    <jats:sup>G12C<\/jats:sup>\n                    -dependent lung cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-50063-z","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:01:53Z","timestamp":1721340113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-846X","authenticated-orcid":false,"given":"Hidenori","family":"Kitai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-1174","authenticated-orcid":false,"given":"Yu C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9863-130X","authenticated-orcid":false,"given":"Priya","family":"Pancholi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Thant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Markov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-227X","authenticated-orcid":false,"given":"Rui","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3155-7576","authenticated-orcid":false,"given":"Hiromichi","family":"Ebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3855-7270","authenticated-orcid":false,"given":"David","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A. M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0234-1589","authenticated-orcid":false,"given":"Mallika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-654X","authenticated-orcid":false,"given":"Neal","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"50063_CR1","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","volume":"14","author":"GJ Riely","year":"2008","unstructured":"Riely, G. J. et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14, 5731\u20135734 (2008).","journal-title":"Clin. Cancer Res."},{"key":"50063_CR2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of ras mutations in cancer. Cancer Res. 80, 2669\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"50063_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"50063_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"50063_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"50063_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604\u2013608 (2016).","journal-title":"Science"},{"key":"50063_CR7","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"50063_CR8","doi-asserted-by":"publisher","unstructured":"J\u00e4nne, P.A., et al. Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2204619 (2022).","DOI":"10.1056\/nejmoa2204619"},{"key":"50063_CR9","doi-asserted-by":"publisher","unstructured":"Reck, M., Carbone, D.P., Garassino, M., and Barlesi, F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol. 32, 1101\u20131110. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.001 (2021).","DOI":"10.1016\/j.annonc.2021.06.001"},{"key":"50063_CR10","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS G12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"50063_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421\u2013425 (2020).","journal-title":"Nature"},{"key":"50063_CR12","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1158\/0008-5472.CAN-17-0768","volume":"77","author":"R Yaeger","year":"2017","unstructured":"Yaeger, R. et al. Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition. Cancer Res. 77, 6513\u20136523 (2017).","journal-title":"Cancer Res."},{"key":"50063_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Clinical acquired resistance to krasg12c inhibition through a novel kras switch-ii pocket mutation and polyclonal alterations converging on ras\u2013mapk reactivation. Cancer Discov. 11, 1913\u20131922 (2021).","journal-title":"Cancer Discov."},{"key":"50063_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679\u2013683 (2021).","journal-title":"Nature"},{"key":"50063_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","volume":"18","author":"QB She","year":"2010","unstructured":"She, Q. B. et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39\u201351 (2010).","journal-title":"Cancer Cell"},{"key":"50063_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman, B. A. et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J. Med. Chem. 63, 52\u201365 (2020).","journal-title":"J. Med. Chem."},{"key":"50063_CR17","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell, J. B. et al. Identification of the clinical development candidate MRTX849, a Covalent KRASG12C inhibitor for the treatment of cancer. J. Med. Chem. 63, 6679\u20136693 (2020).","journal-title":"J. Med. Chem."},{"key":"50063_CR18","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1021\/acs.jmedchem.9b01720","volume":"63","author":"JG Kettle","year":"2020","unstructured":"Kettle, J. G. et al. Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant gtpase krasg12c. J. Med. Chem. 63, 4468\u20134483 (2020).","journal-title":"J. Med. Chem."},{"key":"50063_CR19","doi-asserted-by":"publisher","unstructured":"Schulze, C.J., et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. https:\/\/doi.org\/10.1126\/science.adg9652 (2023).","DOI":"10.1126\/science.adg9652"},{"key":"50063_CR20","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1073\/pnas.0900780106","volume":"106","author":"CA Pratilas","year":"2009","unstructured":"Pratilas, C. A. et al. V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519\u20134524 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50063_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature17963","volume":"534","author":"VS Rodrik-Outmezguine","year":"2016","unstructured":"Rodrik-Outmezguine, V. S. et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534, 272\u2013276 (2016).","journal-title":"Nature"},{"key":"50063_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41589-021-00813-7","volume":"17","author":"BJ Lee","year":"2021","unstructured":"Lee, B. J. et al. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nat. Chem. Biol. 17, 1065\u20131074 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"50063_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1021\/acs.jmedchem.2c01658","volume":"66","author":"GL Burnett","year":"2023","unstructured":"Burnett, G. L. et al. Discovery of RMC-5552, a selective Bi-Steric Inhibitor of mTORC1, for the treatment of mTORC1-activated tumors. J. Med. Chem. 66, 149\u2013169 (2023).","journal-title":"J. Med. Chem."},{"key":"50063_CR24","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1158\/0008-5472.CAN-10-0409","volume":"70","author":"E Halilovic","year":"2010","unstructured":"Halilovic, E. et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK\/ERK and mutant KRAS signaling. Cancer Res. 70, 6804\u20136814 (2010).","journal-title":"Cancer Res."},{"key":"50063_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/sj.onc.1210715","volume":"27","author":"J Averous","year":"2008","unstructured":"Averous, J., Fonseca, B. D. & Proud, C. G. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27, 1106\u20131113 (2008).","journal-title":"Oncogene"},{"key":"50063_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a008714","volume":"5","author":"A Shamas-Din","year":"2013","unstructured":"Shamas-Din, A., Kale, J., Leber, B. & Andrews, D. W. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, 1\u201321 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"50063_CR27","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0804821105","volume":"105","author":"JR Mills","year":"2008","unstructured":"Mills, J. R. et al. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl Acad. Sci. USA 105, 10853\u201310858 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50063_CR28","doi-asserted-by":"publisher","unstructured":"Anderson, G.R., et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci. Transl. Med. 8. https:\/\/doi.org\/10.1126\/scitranslmed.aae0348 (2016).","DOI":"10.1126\/scitranslmed.aae0348"},{"key":"50063_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.molcel.2008.03.025","volume":"30","author":"A H\u00fcbner","year":"2008","unstructured":"H\u00fcbner, A., Barrett, T., Flavell, R. A. & Davis, R. J. Multisite phosphorylation regulates bim stability and apoptotic activity. Mol. Cell 30, 415\u2013425 (2008).","journal-title":"Mol. Cell"},{"key":"50063_CR30","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/febs.14505","volume":"285","author":"JE Conage-Pough","year":"2018","unstructured":"Conage-Pough, J. E. & Boise, L. H. Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming. FEBS J. 285, 2626\u20132640 (2018).","journal-title":"FEBS J."},{"key":"50063_CR31","doi-asserted-by":"publisher","unstructured":"Kumar, P., Hellen, C.U.T., and Pestova, T. V. Toward the mechanism of eIF4F-mediated ribosomal attachment to mammalian capped mRNAs. https:\/\/doi.org\/10.1101\/gad.282418 (2016).","DOI":"10.1101\/gad.282418"},{"key":"50063_CR32","doi-asserted-by":"publisher","unstructured":"Ma, X.M., and Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307\u2013318. https:\/\/doi.org\/10.1038\/nrm2672 (2009).","DOI":"10.1038\/nrm2672"},{"key":"50063_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1126\/science.1130276","volume":"314","author":"NV Dorrello","year":"1979","unstructured":"Dorrello, N. V. et al. S6K1- and bTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467\u2013471 (1979).","journal-title":"Science"},{"key":"50063_CR34","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1128\/MCB.18.12.7565","volume":"18","author":"WE Marissen","year":"1998","unstructured":"Marissen, W. E. & Lloyd, R. E. Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells. Mol. Cell Biol. 18, 7565\u20137574 (1998).","journal-title":"Mol. Cell Biol."},{"key":"50063_CR35","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi, Y. et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin. Cancer Res. 26, 5962\u20135973 (2020).","journal-title":"Clin. Cancer Res."},{"key":"50063_CR36","doi-asserted-by":"publisher","unstructured":"Mendoza, M.C., Er, E.E., and Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320\u2013328. https:\/\/doi.org\/10.1016\/j.tibs.2011.03.006 (2011).","DOI":"10.1016\/j.tibs.2011.03.006"},{"key":"50063_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","volume":"121","author":"L Ma","year":"2005","unstructured":"Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. & Pandolfi, P. P. Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179\u2013193 (2005).","journal-title":"Cell"},{"key":"50063_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1947601911408079","volume":"2","author":"E Castellano","year":"2011","unstructured":"Castellano, E. & Downward, J. Ras interaction with PI3K: More than just another effector pathway. Genes Cancer 2, 261\u2013274 (2011).","journal-title":"Genes Cancer"},{"key":"50063_CR39","doi-asserted-by":"publisher","unstructured":"Elkabets, M., et al. MTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5. https:\/\/doi.org\/10.1126\/scitranslmed.3005747 (2013).","DOI":"10.1126\/scitranslmed.3005747"},{"key":"50063_CR40","doi-asserted-by":"publisher","unstructured":"Corcoran, R.B., et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5. https:\/\/doi.org\/10.1126\/scitranslmed.3005753 (2013).","DOI":"10.1126\/scitranslmed.3005753"},{"key":"50063_CR41","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene 40, 5590\u20135599 (2021).","journal-title":"Oncogene"},{"key":"50063_CR42","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.celrep.2014.04.014","volume":"7","author":"V Pirazzoli","year":"2014","unstructured":"Pirazzoli, V. et al. Acquired resistance of EGFR-mutant lung Adenocarcinomas to Afatinib plus Cetuximab is associated with activation of mTORC1. Cell Rep. 7, 999\u20131008 (2014).","journal-title":"Cell Rep."},{"key":"50063_CR43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41416-018-0322-4","volume":"119","author":"AM Schram","year":"2018","unstructured":"Schram, A. M. et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br. J. Cancer 119, 1471\u20131476 (2018).","journal-title":"Br. J. Cancer"},{"key":"50063_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351\u20131356 (2008).","journal-title":"Nat. Med."},{"key":"50063_CR45","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500\u20131508 (2006).","journal-title":"Cancer Res."},{"key":"50063_CR46","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Investig. 118, 3065\u20133074 (2008).","journal-title":"J. Clin. Investig."},{"key":"50063_CR47","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke, A. B. et al. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228\u20133237 (2012).","journal-title":"Cancer Res."},{"key":"50063_CR48","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.molcel.2021.01.033","volume":"81","author":"R Mukherjee","year":"2021","unstructured":"Mukherjee, R. et al. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol. Cell 81, 708\u2013723.e5 (2021).","journal-title":"Mol. Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50063-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50063-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50063-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:02:00Z","timestamp":1721340120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50063-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50063"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50063-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.R. is on the scientific advisory board (SAB) and owns equity in Beigene, Zai Labs, MapKure, Ribon and Effector. N.R. is also on the SAB of Astra Zeneca and Chugai and a past SAB member of Novartis, Millennium-Takeda, Kura, and Araxes. N.R. is a consultant to RevMed, Tarveda, Array-Pfizer, Boeringher-Ingelheim and Eli Lilly. He receives research funding from Revmed, AstraZeneca, Array Pfizer and Boerhinger-Ingelheim and owns equity in Kura Oncology and Fortress. Y.C.Y., J.J., J.E., B.L., D.W., J.A.M.S., and M.S., are employed by Revolution Medicines. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6076"}}